SUPPLEMENTAL RESULTS

Comparison of Zotarolimus and Everolimus Eluting Coronary Stents: Final 5-Year Report of the RESOLUTE All-Comers Trial

Supplemental Table. ARC Defined Stent thrombosis during 5-year follow-up

Complications	Resolute (ZES) (N=1140 Patients)	Xience-V (EES) (N=1152 Patients)	Difference [95% CI]	P-value
Stent Thrombosis Related to Target Lesion				
ARC Definite ST	1.6% (18/1123)	0.8% (9/1133)	0.8% [-0.1%, 1.7%]	0.084
ARC Probable ST	0.9% (10/1123)	0.9% (10/1133)	0.0% [-0.8%, 0.8%]	1.00
ARC Possible ST	4.5% (50/1123)	3.8% (43/1133)	0.7% [-1.0%, 2.3%]	0.46
ARC Definite + Probable ST	2.4% (27/1123)	1.7% (19/1133)	0.7% [-0.4%, 1.9%]	0.24
ARC Definite + Probable + Possible ST	6.8% (76/1123)	5.4% (61/1133)	1.4% [-0.6%, 3.4%]	0.19
Acute (0 to 1 days)				
ARC Definite ST	0.4% (4/1123)	0.1% (1/1133)	0.3% [-0.1%, 0.7%]	0.22
ARC Probable ST	0.1% (1/1123)	0.1% (1/1133)	0.0% [-0.2%, 0.2%]	1.00
ARC Possible ST	0.0% (0/1123)	0.0% (0/1133)	0.0% [--, --]	-
ARC Definite + Probable ST	0.4% (5/1123)	0.2% (2/1133)	0.3% [-0.2%, 0.7%]	0.29
ARC Definite + Probable + Possible ST	0.4% (5/1123)	0.2% (2/1133)	0.3% [-0.2%, 0.7%]	0.29
Sub-Acute (2 to 30 days)				
ARC Definite ST	0.4% (5/1123)	0.0% (0/1133)	0.4% [0.1%, 0.8%]	0.030
ARC Probable ST	0.3% (3/1123)	0.4% (4/1133)	-0.1% [-0.5%, 0.4%]	1.00
ARC Possible ST	0.0% (0/1123)	0.0% (0/1133)	0.0% [--, --]	-
ARC Definite + Probable ST	0.7% (8/1123)	0.4% (4/1133)	0.4% [-0.2%, 1.0%]	0.26
ARC Definite + Probable + Possible ST	0.7% (8/1123)	0.4% (4/1133)	0.4% [-0.2%, 1.0%]	0.26
Late (31 to 360 days)				
ARC Definite ST	0.4% (5/1123)	0.2% (2/1133)	0.3% [-0.2%, 0.7%]	0.29
ARC Probable ST	0.2% (2/1123)	0.0% (0/1133)	0.2% [-0.1%, 0.4%]	0.25
ARC Possible ST	0.8% (9/1123)	0.8% (9/1133)	0.0% [-0.7%, 0.7%]	1.00
ARC Definite + Probable ST	0.6% (7/1123)	0.2% (2/1133)	0.4% [-0.1%, 1.0%]	0.11
ARC Definite + Probable + Possible ST	1.3% (15/1123)	1.0% (11/1133)	0.4% [-0.5%, 1.2%]	0.44
Very Late (361 to 1800 days)				
ARC Definite ST	0.4% (5/1123)	0.5% (6/1133)	-0.1% [-0.7%, 0.5%]	1.00

Complications	Resolute (ZES) (N=1140 Patients)	Xience-V (EES) (N=1152 Patients)	Difference [95% CI]	P-value
ARC Probable ST	0.4% (4/1123)	0.4% (5/1133)	-0.1% [-0.6%, 0.4%]	1.00
ARC Possible ST	3.7% (41/1123)	3.0% (34/1133)	0.7% [-0.8%, 2.1%]	0.41
ARC Definite + Probable ST	0.8% (9/1123)	1.0% (11/1133)	-0.2% [-0.9%, 0.6%]	0.82
ARC Definite + Probable + Possible ST	4.5% (50/1123)	3.9% (44/1133)	0.6% [-1.1%, 2.2%]	0.53
Stent Thrombosis Related to Non Target Lesions				
ARC Definite ST	0.4% (4/1123)	0.1% (1/1133)	0.3% [-0.1%, 0.7%]	0.22
ARC Definite + Probable ST	0.4% (4/1123)	0.1% (1/1133)	0.3% [-0.1%, 0.7%]	0.22
ARC Definite + Probable + Possible ST	0.4% (4/1123)	0.1% (1/1133)	0.3% [-0.1%, 0.7%]	0.22
Overall Stent Thrombosis				
ARC Definite ST	2.0% (22/1123)	0.9% (10/1133)	1.1% [0.1%, 2.1%]	0.033
ARC Definite + Probable ST	2.8% (31/1123)	1.8% (20/1133)	1.0% [-0.2%, 2.2%]	0.12
ARC Definite + Probable + Possible ST	7.1% (80/1123)	5.5% (62/1133)	1.7% [-0.4%, 3.7%]	0.12
Early (0 to 30 days)				
ARC Definite ST	0.8% (9/1123)	0.1% (1/1133)	0.7% [0.2%, 1.3%]	0.011
ARC Definite + Probable ST	1.1% (12/1123)	0.5% (6/1133)	0.5% [-0.2%, 1.3%]	0.16
ARC Definite + Probable + Possible ST	1.1% (12/1123)	0.5% (6/1133)	0.5% [-0.2%, 1.3%]	0.16
Late (31 to 360 days)				
ARC Definite ST	0.4% (5/1123)	0.2% (2/1133)	0.3% [-0.2%, 0.7%]	0.29
ARC Definite + Probable ST	0.6% (7/1123)	0.2% (2/1133)	0.4% [-0.1%, 1.0%]	0.11
ARC Definite + Probable + Possible ST	1.3% (15/1123)	1.0% (11/1133)	0.4% [-0.5%, 1.2%]	0.44
Very Late (361 to 1800 days)				
ARC Definite ST	0.8% (9/1123)	0.6% (7/1133)	0.2% [-0.5%, 0.9%]	0.63
ARC Definite + Probable ST	1.2% (13/1123)	1.1% (12/1133)	0.1% [-0.8%, 1.0%]	0.84
ARC Definite + Probable + Possible ST	4.8% (54/1123)	4.0% (45/1133)	0.8% [-0.9%, 2.5%]	0.36

All events were adjudicated by the independent Clinical Event Committee. For probable and possible stent thrombosis relation to target lesion or not could not be determined by the committee and all these have all been regarded as target lesion related.